[1] |
GUO Ye, ZHANG Chenping.
Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)
[J]. China Oncology, 2024, 34(4): 425-438.
|
[2] |
HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou.
Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy
[J]. China Oncology, 2023, 33(6): 613-618.
|
[3] |
ZHANG Shaoqiu, YAN Li, LI Ruichen, ZHAO Yang, WANG Xiaoshen, YANG Xuguang, ZHU Yi.
Recent advances and prospect in immune microenvironment and its mechanisms of function in head and neck squamous cell carcinoma
[J]. China Oncology, 2023, 33(6): 629-636.
|
[4] |
ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun.
Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients
[J]. China Oncology, 2022, 32(4): 357-362.
|
[5] |
WANG Jun, HE Ping.
Prognostic value of perineural invasion in ypⅠ-Ⅱ rectal cancer patients who received neoadjuvant radiotherapy
[J]. China Oncology, 2022, 32(12): 1229-1234.
|
[6] |
XUE Tian, SHENG Dong, YAN Wanhui, JIANG Xiangnan, LI Huan’ge, LI Xiaoqiu.
Prognostic factors of follicular lymphoma
[J]. China Oncology, 2020, 30(5): 388-393.
|
[7] |
LI Yuan , GU Wenxian , ZHOU Xiaoli , GENG Xiang , SUN Yangyang .
Clinicopathological observation and prognostic analysis of pure mucinous breast carcinoma with micropapillary pattern
[J]. China Oncology, 2020, 30(11): 897-904.
|
[8] |
SUN Yangyang,GENG Xiang,ZHOU Xiaoli,WANG Gengfang,GU Wenxian,ZHANG Xudong .
Clinicopathologic observation and prognostic factor analysis of primary gastric diffuse large B-cell lymphoma
[J]. China Oncology, 2019, 29(9): 715-722.
|
[9] |
LI Wencheng, WANG Xiaoshen.
The selection and application of platinum drugs in the treatment of head and neck squamous cell carcinomas
[J]. China Oncology, 2019, 29(4): 300-306.
|
[10] |
ZHANG Lei, DONG Yunwei, HU Shenbao, et al.
The impact of American Cancer Joint Committee Revised Thyroid Cancer Staging System (8th edition)on staging of papillary thyroid carcinoma
[J]. China Oncology, 2018, 28(7): 491-496.
|
[11] |
SUN Xin, GUO Wei, YANG Rongli, et al.
Outcomes and prognostic factors of high-grade soft tissue sarcoma: experience at a single institution
[J]. China Oncology, 2018, 28(3): 210-215.
|
[12] |
YUAN Yuan, SHEN Zan.
Retrospective analysis of clinical differences and prognostic factors in 32 patients with maxillofacial osteosarcoma
[J]. China Oncology, 2018, 28(2): 134-139.
|
[13] |
WANG Xiaoshen, HU Chaosu.
Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma
[J]. China Oncology, 2018, 28(12): 881-887.
|
[14] |
GUO Ye.
The immunotherapy for head and neck cancer
[J]. China Oncology, 2017, 27(6): 459-462.
|
[15] |
SONG Yang, LIU Liyang, LI Fenghu, et al.
Expression of HER-2 in 720 cases of breast cancer patients in Guizhou province and retrospective analysis of anti-HER-2 treatment
[J]. China Oncology, 2017, 27(11): 884-889.
|